Esophageal Cancer Clinical Trial Landscape Gains Momentum as 80+ Biopharma Players Advance Next-Generation Therapies | DelveInsight

Esophageal Cancer Clinical Trials

DelveInsight’s latest report, “Esophageal Cancer Pipeline Insight 2026” offers an in-depth evaluation of the evolving therapeutic landscape, highlighting contributions from over 80 companies and more than 100 pipeline candidates targeting esophageal cancer. The report delivers a detailed overview of both clinical and preclinical drug profiles, along with comprehensive assessments based on product type, development phase, route of administration, and molecular classification. Additionally, it sheds light on discontinued and inactive programs within the space.

Discover the latest innovations in esophageal cancer research and stay informed about breakthrough developments in the pipeline: https://www.delveinsight.com/sample-request/esophageal-cancer-pipeline-insight

Key Highlights from the Esophageal Cancer Pipeline Report

• On February 20, 2026, SOFIE initiated a clinical study evaluating the effectiveness of [¹⁸F]FAPI-74 PET/CT imaging for detecting metastatic disease in patients diagnosed with gastric, gastroesophageal junction, or esophageal cancers. Following standardized dosing and screening procedures, participants undergo PET/CT scans, with standard-of-care (SOC) interventions monitored for up to three months post-injection.
• On February 18, 2026, Merck Sharp & Dohme LLC launched a Phase I/II clinical trial to assess the safety and tolerability of investigational therapies combined with pembrolizumab and fluoropyrimidine-based chemotherapy. This study focuses on first-line treatment for patients with HER2-negative, locally advanced unresectable or metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma.
• The report underscores a dynamic pipeline, with more than 80 active companies developing over 100 therapies aimed at improving outcomes in esophageal cancer.
• Prominent players in this domain include OncoTherapy Science/Shionogi & Co., Oncolys BioPharma, Lyvgen Biopharma, Adlai Nortye Biopharma, NovaRock Biotherapeutics, Genmab, Genentech, Jiangsu Hengrui Medicine, Taiho Pharmaceutical, Mirati Therapeutics, Boehringer Ingelheim, and several others.
• Notable therapies under investigation include Panitumumab, Capecitabine, Oxaliplatin, Ramucirumab, Paclitaxel, Pertuzumab, and Trastuzumab, among others.

Access the full clinical trials assessment and stay updated with the latest advancements in cancer care: https://www.delveinsight.com/sample-request/esophageal-cancer-pipeline-insight

Emerging Drug Profiles in Esophageal Cancer

S-588410 (OncoTherapy Science / Shionogi & Co.)

S-588410 is a peptide-based cancer vaccine originally developed by OncoTherapy Science and later licensed to Shionogi. This subunit vaccine is administered subcutaneously and consists of a combination of peptide epitopes derived from tumor-associated antigens targeting HLA-A*2402. Designed as a novel molecular entity, it is currently in Phase III clinical trials for esophageal cancer.

Telomelysin (OBP-301) – Oncolys BioPharma Inc

Telomelysin is a genetically engineered oncolytic adenovirus that selectively replicates in cancer cells using the hTERT promoter. Early clinical findings in melanoma demonstrated systemic anti-tumor effects, including regression of both injected and non-injected tumors. The therapy enhances immune cell infiltration while reducing regulatory T cells. It is currently being evaluated in Phase II trials for esophageal cancer.

LVGN-6051 – Lyvgen Biopharma

LVGN-6051 is an innovative monoclonal antibody targeting the 4-1BB (CD137) pathway. Engineered to activate immune responses specifically within the tumor microenvironment, it balances efficacy and safety by engaging FcγRIIB-expressing immune cells. This therapy is currently in Phase I development.

AN-0025 – Adlai Nortye Biopharma

AN-0025 is a small molecule EP4 receptor antagonist designed to modulate the tumor microenvironment. Originally discovered by Eisai, it has shown promising results in combination with radiation therapy, achieving significant response rates in early trials. The drug is currently being explored in Phase I studies for esophageal cancer.

Download free sample report now: https://www.delveinsight.com/sample-request/esophageal-cancer-pipeline-insight

Comprehensive Insights Offered by the Report

• Detailed profiling of companies engaged in esophageal cancer drug development, along with their respective pipelines
• Categorization of therapies based on development stages: early, mid, and late-stage
• Analysis of both active and discontinued research programs
• Evaluation of pipeline drugs by mechanism of action, molecular type, route of administration, and therapeutic approach (monotherapy vs. combination)
• Insights into strategic collaborations, licensing agreements, and funding activities shaping the future of the market

Explore the report to uncover unmet needs and emerging opportunities in esophageal cancer treatment: https://www.delveinsight.com/sample-request/esophageal-cancer-pipeline-insight

Esophageal Cancer Therapeutic Segmentation

Esophageal Cancer By Route of Administration:

• Intravenous
• Subcutaneous
• Oral
• Intramuscular

Esophageal Cancer By Molecule Type:

• Monoclonal antibodies
• Small molecules
• Peptides

Esophageal Cancer Report Scope

• Global coverage of the esophageal cancer pipeline landscape
• Therapeutic evaluation based on product type (monotherapy, combination, or both)
• Analysis across development stages: Discovery, Preclinical, Phase I, Phase II, and Phase III
• Coverage of major Esophageal Cancer companies including BeiGene, AstraZeneca, Amgen, Pfizer, Novartis, Eli Lilly, Adaptimmune, Innovent Biologics, Janssen Pharmaceuticals, Merck KGaA, and many others
• Detailed review of key therapies such as Panitumumab, Capecitabine, Oxaliplatin, Ramucirumab, Paclitaxel, Pertuzumab, and Trastuzumab

Gain strategic insights into market drivers, barriers, and future growth opportunities by accessing the full report: https://www.delveinsight.com/sample-request/esophageal-cancer-pipeline-insight

Table of Contents

• Introduction
• Executive Summary
• Disease Overview
• Pipeline Therapeutics
• Therapeutic Assessment
• Analytical Perspective
• Late-Stage (Phase III) Candidates
• Mid-Stage (Phase II) Candidates
• Early-Stage (Phase I) Candidates
• Preclinical and Discovery Programs
• Inactive Products
• Key Companies and Therapies
• Unmet Needs
• Market Drivers and Barriers
• Future Outlook and Analyst Insights
• Appendix

About DelveInsight

DelveInsight is a globally recognized healthcare market research and consulting firm specializing in delivering actionable insights across the life sciences sector. With a team of experienced analysts and domain experts, the company provides high-quality, data-driven intelligence to support strategic decision-making. DelveInsight’s customized solutions empower clients to stay competitive and capitalize on emerging opportunities in the rapidly evolving healthcare landscape.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting